Institute of Bioengineering and Bioimaging (IBB)

Main-Page-IBB-Cover

About us

The Institute of Bioengineering and Bioimaging (IBB) is located in Singapore's research and development hub for biomedical sciences, at the heart of Biopolis. The institute is located at Helios and Nanos and is staffed by imaging experts, bioengineers, chemists, physicists, biologists and clinicians. IBB integrates the capabilities and technologies built up by the Institute of Bioengineering and Nanotechnology (IBN) and Singapore Bioimaging Consortium (SBIC), which were established in 2003 and 2004 respectively. IBB's work includes the following scientific breakthroughs and innovations:

  • High-impact papers in leading scientific journals
  • Active patents under the Biomedical Research Council’s portfolio
  • 10 spin-off companies (such as Lucence, InvitroCue and Respiree)
IBB's Vision
To be a world-leading Bioengineering and Bioimaging Institute focused on the translation of technologies for the benefit of human and society.

IBB's Mission
The Institute of Bioengineering & Bioimaging strives to develop new technologies and engineering solutions addressing health, medical and sustainability challenges and to promote the advancement of disease prevention, diagnosis and therapy. With our comprehensive research capabilities at the interface of physical sciences, engineering and bioimaging, the institute brings together multi-disciplinary teams of leading scientists and engineers to tackle national and international health and technological priorities through partnership with both clinical and industry communities.

Our Focus Areas

Biomedical Devices & Diagnostics

Learn more

Bioengineering Systems

Learn more

Biophotonics & Bioimaging

Learn more

IBB spearheads multi-disciplinary, application-driven research at the interface of biology, chemistry, engineering and medicine, and work closely with stakeholders across the ecosystem to deliver innovative solutions in strategic areas such as cancer, infectious diseases, and food and nutrition.

Highlights

IBB researchers awarded Wellcome Leap R3 Programme ContractmRNA_Vaccine_Thumbnail

Congratulations to Dr Yi Yan Yang and team on being awarded the Wellcome Leap R3 Programme Contract. They are part of a team of scientists in Singapore that are looking to address the limitations of mRNA vaccines.



Learn More
Spin-off Spotlight: LucenceLucence_Thumbnail

The work of Lucence, a spin-off company from IBB that recently made headlines for COVID-19 pre-departure saliva testing. We spoke to one of our scientists, Dr Rachel Sim, who reflected on her contribution to the project.







Learn More
Life Outside the Lab

IBB-News-thumbnail_LOTL_Rachel

Finding the balance between work and life outside the lab can be challenging for some, but it is important for maintaining good mental health. Speaking to one of our research officers, Rachel Tan, we learn how she makes time for the things that she enjoys outside of work.





Learn More

LinkedIn Banner